Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced its appointment of Dr. Maher Khaled to the position of director of international operations. Khaled bolsters the PreveCeutical team with more than a decade of experience in commercializing therapeutic and diagnostic technologies, most recently at UniQuest Pty Ltd. Moving forward, he will be involved in overseeing PreveCeutical’s development of therapeutic technologies, as well as managing the company’s ongoing operations in Australia, reviewing acquisition and licensing opportunities and leading commercialization efforts for its growing IP portfolio. “We are delighted to have Dr. Khaled as part of our team,” Stephen Van Deventer, chairman and CEO of PreveCeutical, stated in the news release. “Dr. Khaled’s degrees in law and science, as well as his experience in commercialising therapeutic and diagnostic technologies will be of tremendous benefit to PreveCeutical and its shareholders.”
To view the full press release, visit http://cnw.fm/75lbU
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information, visit the company’s website at www.PreveCeutical.com
More from CannabisNewsBreaks
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com